Approval of the merger of Aventis with and into sanofi-aventis

Paris, December 23, 2004 Approval of the merger of Aventis with and into sanofi-aventis Sanofi-aventis announces that on December 23, 2004, the extraordinary general meeting of its shareholders approved all resolutions relating to the proposed merger of Aventis with and into sanofi-aventis, including the exchange ratio of 27 sanofi-aventis shares for 23 Aventis shares. The Aventis shareholders having approved all the resolutions relating to this merger on December 13, 2004, all of the conditions precedent provided in the merger agreement have been satisfied, and the merger will take effect on December 31, 2004. The merger, which is intended to help align the legal structure of the group with its operating structure, is a logical follow-on to Sanofi-Synthelabo’s public offer for Aventis and represents an important step for the group. Important Information. In connection with the merger of Aventis with and into Sanofi-Aventis, Sanofi-Aventis has filed a post-effective amendment to its registration statement on Form F-4 (File no. 333-112314), which includes a definitive prospectus relating to the Sanofi-Aventis shares to be issued to Aventis shareholders resident in the U.S. in connection with the proposed merger, and may file additional documents with the SEC. Investors are urged to read the registration statement, including the definitive prospectus, and any other relevant documents filed with the SEC, including all amendments and supplements, because they will contain important information. Free copies of the registration statement, as well as other relevant documents filed with the SEC, may be obtained at the SEC’s web site at www.sec.gov. The prospectus relating to the Sanofi-Aventis shares to be issued to Aventis shareholders in connection with the proposed merger has been mailed to Aventis security holders resident in the U.S. and additional copies may be obtained for free from MacKenzie Partners, Inc., the U.S. information agent for the merger, at the following address: 105, Madison Avenue, New York, New York 10016; telephone: 1-(212) 929-5500 (call collect) or 1-(800) 322-2885 (toll-free call); e-mail proxy@mackenziepartners.com. Sanofi-aventis and Aventis have prepared a prospectus (Schéma E) registered with the French Autorité des marchés financiers (AMF) under reference number E.04-200 on November 9, 2004, which constitutes an annex to the reports of the board of directors of sanofi-aventis and of the management board of Aventis presented to the general meetings of the shareholders of sanofi-aventis and Aventis that will vote on the merger of Aventis with and into sanofi-aventis. This prospectus contains information on the merger and its consequences and contemplates the subsequent listing on the Premier marché of Euronext Paris of the shares to be issued in connection with the merger. It is strongly recommended that shareholders and investors read this prospectus which is available at the registered offices of sanofi-aventis and Aventis as well as on the internet websites of sanofi-aventis (www.sanofi-aventis.com) and the AMF (www.amf-france.org). A copy of the prospectus may also be obtained free of charge by mail from BNP Paribas Securities Services, GIS Emetteurs, Service assemblées, Immeuble Tolbiac, 75450 Paris Cedex 09. Investors and shareholders may also obtain any other document filed or registered by sanofi-aventis or Aventis, respectively, free of charge from the AMF at its website (www.amf-france.org) or directly from sanofi-aventis or Aventis, as the case may be, at the internet websites of www.sanofi-aventis.com and www.Aventis.com, respectively. ------------------------------------------------------------ Ytterligere informasjon kan hentes på følgende hjemmeside: http://www.waymaker.no

Om oss

Et stort farmasøytisk selskap som setter fokus på helse over hele verden. Med en nettoomsetning i 2004 på 26 750 millioner euro, og mer enn 100 000 ansatte i rundt 100 land er Sanofi-aventis er et av verdens ledende legemiddel selskap og er blant topp 6 i Norge. Det globale hovedkontoret er i Paris, Frankrike. Det norske hovedkontoret befinner seg på Lysaker. 7 viktige behandlingsområder Sanofi-aventis fokuserer sine aktiviteter på 7 viktige behandlingsområder: Hjerte-karsykdommer (f. eks. Hypertensjon)Thrombose (Blodpropp)Onkologi (Kreft)Sykdommer i sentralnervesystemet (f.eks. MS) DiabetesOsteoporose (Benskjørhet) Gode legemidler for millioner av pasienter Sanofi-aventis’ portefølje av markedsførte produkter inkluderer flere legemidler som er verdensledere i sine respektive klasser, innen områdene blodpropp, hjerte-karsykdommer, søvnforstyrrelser, epilepsi, diabetes og kreft. Svært produktiv og nyskapende forskning og utvikling Grunnlaget for sanofi-aventis' verdensomspennende fremgang er en svært produktiv og nyskapende forsknings- og produktutviklingsorganisasjon med rundt 11 000 forskere som jobber i mer enn 20 forskningssentere på tre kontinenter. Her legger vi vekt på å forske frem nyskapende terapeutiske behandlinger. For øyeblikket er rundt tretti forsknings- og produktutviklingsprosjekter kommet meget langt i utviklingen. Se forøvrig hjemmesiden til Legemiddelindustriforeningen. For mer informasjon om sanofi-aventis rundt om i verden kan du besøke www.sanofi-aventis.com.

Abonner